cangrelor tetrasodium

SKU: orb1302150

Description

Cangrelor tetrasodium is a potent, reversible P2Y12 receptor antagonist that provides rapid antiplatelet action. It is widely used in cardiovascular research to study thrombosis and platelet biology in both in vitro assays and in vivo animal models.

Research Area

Metabolism Research, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 163706-36-3
• MW: 864.29
• Purity: >99.99% (May vary between batches)
• Formula: C₁₇H₂₁Cl₂F₃N₅Na₄O₁₂P₃S₂
• SMILES: [Na+].[Na+].[Na+].[Na+].CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O
• Target: P2Y Receptor,GPCR
• Solubility: H2O:80 mg/mL (92.56 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.16 mM);DMSO:12.56 mg/mL (14.53 mM)

Bioactivity

• In Vitro:
  cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10 mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

platelet, pulmonary, P2Y Receptor, P2Y, P2YReceptor, aggregation, antiplatelet, cangrelor tetrasodium, cangrelor, GPR17, fibrosis, Inhibitor, inflammation, intravenous, inhibit

Compound Identifiers

PubChem CID

10260031